News

Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Program

Gaithersburg, Md. – Oct. 3, 2019 – Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Company’s ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in acute myeloid leukemia. More...
 

Magenta Medical Closes Funding Round Led by NEA In Its First-Ever Life Sciences Investment in Israel

Kadima, Israel – July 29, 2019 – Magenta Medical, the developer of heart failure solutions based on proprietary miniaturized blood pump technology, today announced a financing round led by global venture capital firm New Enterprise Associates (NEA), with participation from existing investors, including Pitango Venture Capital, JVC Investment Partners and a group of private investors led by Prof. Jacques Seguin (CoreValve, ReCor). More...

 

Ferring acquires innovative biotechnology company and
microbiome pioneer Rebiotix Inc.

Saint-Prex, Switzerland & Roseville, MN, US – 05 April, 2018 – Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients. More...

 

Novartis-AveXis deal could be game-changer for Chicago

Chicago scored a major win April 9, but it barely registered with most local business leaders. The triumph was Novartis' eye-popping $8.7 billion buyout of a largely unknown startup called AveXis. It was far and away the biggest acquisition yet of a Chicago-area biotech company, more than three times the size of the next largest deal—the 2015 sale of Lake Forest-based PharMEDium to AmerisourceBergen for $2.58 billion. More...

 

AmerisourceBergen to buy PharMEDium for $2.58 billion

David Jonas doesn't like to sit idle. He plays tennis, not golf. He's an early riser, often starting his day with a run of 4 to 5 miles on an empty stomach. When he retired from Baxter International after 25 years, he started a new company. It just sold for $2.58 billion. More...

 

PharMEDium - LEK Consulting 

L.E.K.’s CEO Stuart Jackson, discusses PharMEDium's extraordinary growth trajectory: More...